Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell ly...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:N Engl J Med
Egile Nagusiak: Wang, Michael L., Rule, Simon, Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S., Jurczak, Wojciech, Advani, Ranjana H., Romaguera, Jorge E., Williams, Michael E., Barrientos, Jacqueline C., Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E., Li, Lei, Zhang, Liang, Newberry, Kate, Ou, Zhishuo, Cheng, Nancy, Fang, Bingliang, McGreivy, Jesse, Clow, Fong, Buggy, Joseph J., Chang, Betty Y., Beaupre, Darrin M., Kunkel, Lori A., Blum, Kristie A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4513941/
https://ncbi.nlm.nih.gov/pubmed/23782157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1306220
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak